Eli Lilly and Company

Mark M Foreman

Michael E Flaugh

David T Wong

William L Garbrecht

Gifford P Marzoni

Kathleen R Whitten

J David Leander

The present invention provides methods of preventing emesis and treating sexual dysfunction in mammals utilizing certain tetrahydrobenz�cd!indoles. The invention further provides pharmaceutical formulations suitable for use in such methods.

Method of preventing emesis using tetrahydrobenz

This invention provides 6-substituted-4-(amino or substituted amino)tetrahydrobenz[c,d]indole serotonin agonists useful in treating a variety of conditions associated with serotonin function.

Tetrahydrobenz[c,d]indole serotonin agonists

This invention provides a method of treating lower urinary tract disorders in mammals employing compounds which inhibit norepinephrine reuptake and having negligible anticholinergic effect.

Treatment of lower urinary tract disorders with selective norepinephrine

Tetrahydrobenz(c,d)indole serotonin agonists

This invention provides (8.beta.)-N-cycloalkyl-1-alkyl-6-(substituted) ergoline-8-carboxamides useful for blocking 5HT.sub.2 receptors in mammals having an excess of serotonin centrally or peripherally. The invention also provides methods for treating hypertension, migraine, vasospasm, thrombosis, ischemia, depression, anxiety, sleep disorders and appetite disorders with a compound of the invention.

Cycloalkylamides of (8.beta.)-1-alkyl-6-(substituted) ergolines

Dopamine D-1 agonists, trans-(+)tautomers of the formula ##STR1##

Stimulating dopamine D-1 receptors

Sexual dysfunction in mammals is treated with a trans-(.+-.)- or trans-(-)-2-amino-4-permissibly-substituted-6-loweralkyl or allyl octahydropyrimido[4,5-g]quinoline or a pharmaceutically-acceptable acid addition salt thereof.

Growing community of inventors

Indianapolis, IN, United States of America

Mark M Foreman